Biotech News

DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences

DiaMedica Therapeutics (DMAC)DiaMedica TherapeuticsCompany update

DMAC (DMAC) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is dmac.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

DiaMedica Therapeutics

Recombinant Kallikrein Therapy DiaMedica Therapeutics develops DM199, a recombinant form of human tissue kallikrein intended to restore biological pathways involved in vascular regulation, placental function and tissue perfusion. Preeclampsia Program Multiple Phase 2 studies are evaluating DM199 in early-onset preeclampsia. These studies...

Recent company news

Stock data

Close
6.52 USD
Market cap
310.91M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States